Search company, investor...
Selecta Biosciences company logo

Selecta Biosciences

selectabio.com

Stage

IPO | IPO

Total Raised

$134.13M

Date of IPO

6/22/2016

Market Cap

0.19B

Stock Price

1.26

About Selecta Biosciences

Selecta Biosciences is a biopharmaceutical company developing a new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's Synthetic Vaccine Particle (SVP) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta's fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta's SVP platform technology is flexible to enable diverse vaccines and the company has created antigen-specific targeted Synthetic Vaccine Particles (tSVP) and antigen-specific targeted tolerogenic Synthetic Vaccine Particles (t2SVP).

Headquarters Location

65 Grove St

Watertown, Massachusetts, 02472,

United States

617-923-1400

Missing: Selecta Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Selecta Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Selecta Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Selecta Biosciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Selecta Biosciences Patents

Selecta Biosciences has filed 1 patent.

The 3 most popular patent topics include:

  • Immunology
  • Immunosuppressants
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/11/2018

8/30/2022

Glucocorticoids, Pregnanes, Fluoroarenes, Corticosteroid esters, Diketones

Grant

Application Date

3/11/2018

Grant Date

8/30/2022

Title

Related Topics

Glucocorticoids, Pregnanes, Fluoroarenes, Corticosteroid esters, Diketones

Status

Grant

Latest Selecta Biosciences News

Selecta Biosciences Appoints Blaine Davis as Chief Financial Officer

Nov 29, 2022

November 28, 2022 Blaine Davis WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. “Blaine is a highly accomplished biopharmaceutical executive with proven financial and business development expertise,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “We are preparing for a number of key potential milestones across our pipeline including our expected Phase 3 readout in chronic refractory gout, our expected Phase 1/2 trial initiation in methylmalonic acidemia, and our planned IL-2 candidate selection for the treatment of autoimmune disease with ImmTOR-IL. We are delighted to welcome Blaine to the team as we seek to take this potentially generational leap forward for our precision immune tolerance platform and deliver on our mission to restore natural immune tolerance in patients suffering from debilitating diseases. Blaine’s impressive track record makes him an ideal fit for Selecta at this critical inflection point.” Mr. Davis added, “I am thrilled to join the Selecta team at this pivotal moment in the company’s growth trajectory. I look forward to bringing my experience to Selecta and working closely with the entire team to reach our goal of delivering long-term value for shareholders and ultimately improving the lives of our patients.” Mr. Davis brings more than 25 years of experience in investor relations, business development, corporate affairs and sales and marketing at life sciences companies, with a particular focus on rare diseases. Prior to joining Selecta, Mr. Davis served as Chief Financial Officer of Protara Therapeutics, Inc. where he built the finance function from the ground up across all financial verticals. Previously, he served as Vice President, Head of Investor Relations and Corporate Communications at Insmed Incorporated and held multiple executive leadership positions at Endo International plc, including Senior Vice President and General Manager, Specialty Pharmaceuticals; President of Endo Ventures; and Senior Vice President, Investor Relations and Corporate Communications. Prior to his tenure at Endo International plc, Mr. Davis held a number of roles in Business Development and Investor Relations at Bristol-Myers Squibb Company. Mr. Davis holds a B.A. in Biology and Psychology from Middlebury College. About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit  www.selectabio.com .

Selecta Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Selecta Biosciences Rank

Selecta Biosciences Frequently Asked Questions (FAQ)

  • Where is Selecta Biosciences's headquarters?

    Selecta Biosciences's headquarters is located at 65 Grove St, Watertown.

  • What is Selecta Biosciences's latest funding round?

    Selecta Biosciences's latest funding round is IPO.

  • How much did Selecta Biosciences raise?

    Selecta Biosciences raised a total of $134.13M.

  • Who are the investors of Selecta Biosciences?

    Investors of Selecta Biosciences include Polaris Partners, +ND Capital, Flagship Pioneering, OrbiMed Advisors, Rusnano and 13 more.

  • Who are Selecta Biosciences's competitors?

    Competitors of Selecta Biosciences include Humanetics, Hydra Biosciences, OyaGen, Tobira Therapeutics, Micromet and 11 more.

Compare Selecta Biosciences to Competitors

P
Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

L
LaGray

LaGray is engaged in the research and development of drugs for the treatment of endemic diseases in Sub-Saharan Africa.

Topica Logo
Topica

Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.

O
OyaGen

OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

P
Photopharmica

Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications

A
AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.